Taken together, we suggest that the beneficial effects of PACAP upon cerebral toxoplasmosis rely partially on the differential expression of PACAP receptors on the immune cells directly involved in the disease control. The gene discussed is ADCYAP1; the disease is cerebral toxoplasmosis.